/
CVKD
$1.84+$0.02 (+1.09%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$6.6M
4M shares
52-week range
$1.76 – $14.64
1% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Change$-59.94
Cadrenal Therapeutics, Inc. Common Stock
Cadrenal Therapeutics Inc is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. Its product candidate, CAD-1005, is a first-in-class selective 12-LOX inhibitor being developed to treat heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. The pipeline includes two additional clinical-stage assets: tecarfarin and frunexian. Tecarfarin is an oral vitamin K antagonist (VKA) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Frunexian is a first-in-class, Phase 2-ready intravenous Factor XIa inhibitor designed for acute care settings where contact activation of coagulation by medical devices or artificial surfaces.
www.cadrenal.com- Employees
- 5
- IPO / List date
- Jan 20, 2023
- HQ
- PONTE VEDRA, FL
Held by traders on TradeandTell
No one on the platform currently holds CVKD.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in CVKD as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2024-08-20 | 1-for-15reverse |
Recent trades on TradeandTell
No one on the platform has traded CVKD yet.
